Recently, Difei Medical Technology (Nanjing) Co., Ltd. (hereinafter referred to as 'Difei Medical') announced the completion of tens of millions of RMB A+ round of financing. This round of financing was invested by Ruiyoukang Fund, a subsidiary of Jiangbei Science and Technology Investment Group. It is used for Difei medical technology research and development, product registration and clinical cooperation promotion, etc.Founded in 2018, Difei Medical was conceived and incubated by Shihe Gene, a leader in the field of tumor precision medicine in China. It is a high-tech enterprise focusing on the development and service of clinical molecular detection technology for pathogenic microorganisms.The company's headquarters is located in Jiangbei New District, a national-level new area. It has a R&D and commercial operation team of more than 100 people from top universities at home and abroad and multidisciplinary.Following prenatal screening and precise diagnosis of tumors, technological advances in high-throughput sequencing and liquid biopsy have promoted the vigorous development of the field of pathogenic microorganisms.The technology has the advantages of not relying on culture, directly acting on clinical samples, unbiased detection, and being able to detect rare and new pathogens.

Recently, the Clinical Laboratory Center of the National Health and Medical Commission announced the results of the external quality evaluation of metagenomic sequencing of lower respiratory tract infections nationwide. A total of 90 enterprises and hospitals across the country participated in the evaluation, with a pass rate of 44.4%. Difei Medical successfully passed the external quality evaluation with high scores .

The team of Professor Li Yuchuan from the Department of Infectious Diseases of the Children's Hospital of Fudan University collaborated with Diffei Medical to treat a case of Burkholderia pseudomallei sepsis in a child [1].The peripheral blood of the child was sent to Diffei Medical Laboratory for testing, and mNGS quickly identified Burkholderia pseudomallei.This case was Burkholderia pseudomallei sepsis in a child in a non-endemic area. The child's brother died from the same disease.Burkholderia pseudomallei sepsis is relatively rare in children and has a high mortality rate. Although it is rare in non-endemic areas, it should be highly valued clinically, and etiological examination should be completed as soon as possible and active anti-infective treatment should be given.This case has been included in the 'Chinese Clinical Case Results Database'.

In February 2023, Chen Xiaobo's team from the Thoracic Surgery Department of the First Affiliated Hospital of Kunming Medical University cooperated with Difei Medical and published a research article in Environmental science and pollution research international (IF=5.19) magazine.The study used 16S rRNA technology to detect the lung flora of 40 patients with lung adenocarcinoma in Kunming and found that Bifidobacterium may play an important role in lymph node metastasis and tumor progression, providing potential biomarkers for the diagnosis of lung adenocarcinoma.

Recently, the team of the Department of Rheumatology and Immunology of China-Japan Friendship Hospital cooperated with Diffei Medical and published 'High prevalence and mortality of Pneumocystis jirovecii pneumonia in anti-MDA5 antibody-positive dermatomyositis' in Rheumatology (IF=7.064).

A few days ago, the Nanjing Science and Technology Bureau announced the 2023 Nanjing Engineering Technology Research Center Certification List.'Nanjing Infection Metagenome Engineering Technology Research Center' built by Difei Medical Technology (Nanjing) Co., Ltd. has been recognized through the procedures of district-level competent department recommendation, expert review, director's office meeting deliberation, and public announcement!

The development of modern science and technology promotes medical progress. Metagenomic next-generation sequencing (mNGS) technology has gradually entered the clinic from the laboratory and into the public eye, playing a key role in the diagnosis of many patients with difficult infections .

Difei Medical Technology (Nanjing) Co., Ltd. is a star enterprise under Nanjing Shihe Gene Biotechnology Co., Ltd.As a pioneer in the field of pathogenic microorganism detection in China, Difei Medical adheres to the corporate mission of 'born from the sense' and aims at 'innovating technology, transforming medical treatment' to create a more professional and clinically suitable testing product line , Escort the health of the public with advanced medical technology and services.